Gene editing currently occupies just a small corner of the regenerative medicine pipeline, but it represents a game-changing technology that could produce therapies to treat patients with genetically defined diseases who no longer have any other options. Given the high stakes and the high revenue potential, key academic and industry stakeholders are involved in an intense patent battle that is expected to play out for several years. The outcomes will significantly shape the gene editing market.
Gene editing involves adding, removing, or altering DNA using an engineering nuclease that performs a cut in the DNA, plus either a protein or RNA molecule that recognizes and acts as a guide to the area to be edited
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?